All enrolled patients who received a minimum of one dose of zosuquidar or placebo throughout induction were monitored with the incidence of adverse functions (439 patients, 219 on zosuquidar and 210 on placebo). The most common adverse occasions ended up relevant to the period of prolonged and major myelosuppression as https://eldern776akv3.thelateblog.com/profile